Olga G. Goryacheva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olga G. Goryacheva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Ifeanyi Obeagu
Division of Haematology, Department of Biomedical and Laboratory Science, Africa University
2 shared publications - A. V. Markova
Petrovsky National Research Centre of Surgery
1 shared publication - E. G. Malelin
Ye. A. Vagner Perm State Medical University
1 shared publication - F. Ya. Tukhasheva
Petrovsky National Research Centre of Surgery
1 shared publication - G. A. Terekhin
Perm State Pharmaceutical Academy
1 shared publication - I. F. Litsinger
M.A. Tver’e City Clinical Hospital
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 459-469
Osteomyelitis in HIV pathogenesis, challenges, and therapeutic strategies
Osteomyelitis, a severe bone infection, presents a significant challenge in individuals living with HIV due to immunosuppression and an increased susceptibility to opportunistic pathogens. HIV infection leads to a weakened immune system, which, in conjunction with chronic inflammation and compromised bone health, increases the risk of developing osteomyelitis. This review delves into the complex pathogenesis of osteomyelitis in HIV patients, exploring the interplay between immune dysfunction, microbial invasion, and the subsequent bone damage that occurs. The diagnosis of osteomyelitis in HIV-infected individuals is often delayed due to nonspecific symptoms and the challenge of distinguishing it from other conditions. Imaging techniques, such as MRI and CT scans, are essential for identifying bone involvement, but microbiological confirmation can be challenging due to atypical pathogens. As a result, timely intervention becomes difficult and often leads to more severe infections and complications. This review highlights these diagnostic challenges and emphasizes the need for a more efficient and accurate approach to detection.
- 18 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 459-469
Open AccessOsteomyelitis in HIV pathogenesis, challenges, and therapeutic strategies
Osteomyelitis, a severe bone infection, presents a significant challenge in individuals living with HIV due to immunosuppression and an increased susceptibility to opportunistic pathogens. HIV infection leads to a weakened immune system, which, in conjunction with chronic inflammation and compromised bone health, increases the risk of developing osteomyelitis. This review delves into the complex pathogenesis of osteomyelitis in HIV patients, exploring the interplay between immune dysfunction, microbial invasion, and the subsequent bone damage that occurs. The diagnosis of osteomyelitis in HIV-infected individuals is often delayed due to nonspecific symptoms and the challenge of distinguishing it from other conditions. Imaging techniques, such as MRI and CT scans, are essential for identifying bone involvement, but microbiological confirmation can be challenging due to atypical pathogens. As a result, timely intervention becomes difficult and often leads to more severe infections and complications. This review highlights these diagnostic challenges and emphasizes the need for a more efficient and accurate approach to detection.
- Open Access
- 11 September 2025
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 42 (4) , 55-63
Analysis of the causes of lethal outcome in patients infected with human immunodeficiency virus
Over 37 million HIV-infected people live in the world and many of them die due to the progression and decompensation of somatic diseases. The aim of the study is to determine the rating of fatal outcomes causes of HIV-infected patients according to the data of the authors from different countries of the world. Data from 287 full-text articles were analyzed, from which 32 sources most relevant to the purpose of the study were selected. The leading causes of death in HIV-infected patients were infectious complications and opportunistic infections characteristic of the AIDS stage, along with concomitant tuberculosis infection (55.1 %). Cardiovascular diseases ranked second (20.6 %), followed by cancer (14.6 %), liver diseases, including alcoholic and viral hepatitis and cirrhosis (8.5 %), and only 1.1% are accounted for by all other diseases. Mortality from infective endocarditis, myocardial infarction, sudden cardiac death, acute cerebrovascular event, pulmonary embolism and acute decompensation of chronic heart failure together account for 82.5 % of all cardiovascular causes of mortality. Monitoring of patients with HIV infection should be comprehensive, involving infectious disease specialists, therapeutic and cardiology services, with increased cancer vigilance. The challenges of HIV infection concerning early development of cardiovascular pathology and elevated mortality from cardiovascular diseases should not be ignored.
- 11 September 2025
- Published by ECO-Vector LLC (Publications) in Perm Medical Journal
- Vol. 42 (4) , 55-63
Open AccessAnalysis of the causes of lethal outcome in patients infected with human immunodeficiency virus
Over 37 million HIV-infected people live in the world and many of them die due to the progression and decompensation of somatic diseases. The aim of the study is to determine the rating of fatal outcomes causes of HIV-infected patients according to the data of the authors from different countries of the world. Data from 287 full-text articles were analyzed, from which 32 sources most relevant to the purpose of the study were selected. The leading causes of death in HIV-infected patients were infectious complications and opportunistic infections characteristic of the AIDS stage, along with concomitant tuberculosis infection (55.1 %). Cardiovascular diseases ranked second (20.6 %), followed by cancer (14.6 %), liver diseases, including alcoholic and viral hepatitis and cirrhosis (8.5 %), and only 1.1% are accounted for by all other diseases. Mortality from infective endocarditis, myocardial infarction, sudden cardiac death, acute cerebrovascular event, pulmonary embolism and acute decompensation of chronic heart failure together account for 82.5 % of all cardiovascular causes of mortality. Monitoring of patients with HIV infection should be comprehensive, involving infectious disease specialists, therapeutic and cardiology services, with increased cancer vigilance. The challenges of HIV infection concerning early development of cardiovascular pathology and elevated mortality from cardiovascular diseases should not be ignored.
- Open Access
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 5624-5630
Pancytopenia in HIV-positive patients with congestive heart failure: mechanisms, diagnosis, and treatment approaches
Pancytopenia, characterized by the simultaneous reduction of red blood cells, white blood cells, and platelets, is a significant hematological complication in individuals living with human immunodeficiency virus (HIV). Its presence often reflects disease progression, immune suppression, and concurrent opportunistic infections. When pancytopenia coexists with congestive heart failure (CHF) – a condition increasingly prevalent among HIV-positive patients due to chronic inflammation, antiretroviral therapy (ART)-associated cardiotoxicity, and aging – the clinical burden intensifies, leading to diagnostic and therapeutic dilemmas. This review aims to examine the underlying mechanisms, diagnostic challenges, and management strategies of pancytopenia in HIV-positive patients with CHF. It explores the multifactorial pathophysiology, including direct viral effects on the bone marrow, drug-induced cytopenias, opportunistic infections, nutritional deficiencies, and CHF-related impairments in erythropoietin and thrombopoietin production. Additionally, the review highlights overlapping symptoms that complicate diagnosis and evaluates current treatment options ranging from ART optimization to hematopoietic growth factors and supportive care.
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (9) , 5624-5630
Open AccessPancytopenia in HIV-positive patients with congestive heart failure: mechanisms, diagnosis, and treatment approaches
Pancytopenia, characterized by the simultaneous reduction of red blood cells, white blood cells, and platelets, is a significant hematological complication in individuals living with human immunodeficiency virus (HIV). Its presence often reflects disease progression, immune suppression, and concurrent opportunistic infections. When pancytopenia coexists with congestive heart failure (CHF) – a condition increasingly prevalent among HIV-positive patients due to chronic inflammation, antiretroviral therapy (ART)-associated cardiotoxicity, and aging – the clinical burden intensifies, leading to diagnostic and therapeutic dilemmas. This review aims to examine the underlying mechanisms, diagnostic challenges, and management strategies of pancytopenia in HIV-positive patients with CHF. It explores the multifactorial pathophysiology, including direct viral effects on the bone marrow, drug-induced cytopenias, opportunistic infections, nutritional deficiencies, and CHF-related impairments in erythropoietin and thrombopoietin production. Additionally, the review highlights overlapping symptoms that complicate diagnosis and evaluates current treatment options ranging from ART optimization to hematopoietic growth factors and supportive care.
- 24 April 2025
- Published by Alfmed LLC in Medical alphabet
- No. 3,p. 30-34
The clinical significance of determining arterial stiffness in patients infected with the human immunodeficiency virus
Introduction. Arterial wall stiffness is an indicator that depends not only on age and blood pressure, but also on the activity of the inflammatory process, the rigidity of the muscular layer of arterioles, the presence of heart and kidney failure, type II diabetes mellitus, as well as genetic predisposition.The aim of the study was to evaluate arterial stiffness by the traditional method of oscillometric registration of pulse wave velocities in the aorta, brachial artery and their augmentation indices, to determine the clinical and prognostic significance of its increase in patients infected with the human immunodeficiency virus.Materials and methods. In order to determine the relationship of arterial stiffness indices with clinical, laboratory and instrumental data in patients infected with the human immunodeficiency virus (HIV), 240 patients were examined. After examination using noninvasive arteriographic oscillometry by the Tensiomed Arteriograph 24 medical device, the patients were divided into two groups, depending on the presence and absence of signs of brachial artery stiffness. Increased arterial stiffness was determined when the pulse wave velocity on the brachial artery increased by more than 10 m/s and the brachial artery augmentation index increased by more than 10%. Rigidity was assessed by the indicator of total peripheral vascular resistance.Results. HIV-infected patients in 12.7% of cases have signs of increased arterial stiffness. Increased arterial stiffness was more common in smoking patients and less common in alcohol drinkers. Left atrial dilation and signs of pulmonary heart failure were more often detected in the group with increased arterial stiffness. The chances of an increase in the volume of the left atrium against the background of increased arterial stiffness increase 2.7 times. In patients with increased arterial stiffness, a lower serum iron content, increased activity of matrix metalloproteinase1, as well as an increase in the rate of erythrocyte sedimentation were noted.Conclusion. In patients with HIV infection, it is advisable to assess the stiffness of the arterial wall using an oscillometric method in order to predict the development of left atrial dilation.
- 24 April 2025
- Published by Alfmed LLC in Medical alphabet
- No. 3,p. 30-34
The clinical significance of determining arterial stiffness in patients infected with the human immunodeficiency virus
Introduction. Arterial wall stiffness is an indicator that depends not only on age and blood pressure, but also on the activity of the inflammatory process, the rigidity of the muscular layer of arterioles, the presence of heart and kidney failure, type II diabetes mellitus, as well as genetic predisposition.The aim of the study was to evaluate arterial stiffness by the traditional method of oscillometric registration of pulse wave velocities in the aorta, brachial artery and their augmentation indices, to determine the clinical and prognostic significance of its increase in patients infected with the human immunodeficiency virus.Materials and methods. In order to determine the relationship of arterial stiffness indices with clinical, laboratory and instrumental data in patients infected with the human immunodeficiency virus (HIV), 240 patients were examined. After examination using noninvasive arteriographic oscillometry by the Tensiomed Arteriograph 24 medical device, the patients were divided into two groups, depending on the presence and absence of signs of brachial artery stiffness. Increased arterial stiffness was determined when the pulse wave velocity on the brachial artery increased by more than 10 m/s and the brachial artery augmentation index increased by more than 10%. Rigidity was assessed by the indicator of total peripheral vascular resistance.Results. HIV-infected patients in 12.7% of cases have signs of increased arterial stiffness. Increased arterial stiffness was more common in smoking patients and less common in alcohol drinkers. Left atrial dilation and signs of pulmonary heart failure were more often detected in the group with increased arterial stiffness. The chances of an increase in the volume of the left atrium against the background of increased arterial stiffness increase 2.7 times. In patients with increased arterial stiffness, a lower serum iron content, increased activity of matrix metalloproteinase1, as well as an increase in the rate of erythrocyte sedimentation were noted.Conclusion. In patients with HIV infection, it is advisable to assess the stiffness of the arterial wall using an oscillometric method in order to predict the development of left atrial dilation.
- Open Access
- 14 February 2025
- Published by Alfmed LLC in International journal of Innovative Medicine
- No. 1,p. 10-16
Diastolic dysfunction of the left ventricle in HIV-infected patients, clinical and prognostic relationships
Diastolic dysfunction in HIV-infected patients is a common problem, the pathway of which is based on chronic low-intensity inflammation, and whose consequences are associated with progression of chronic heart failure (CHF) and death. The aim of the study was to evaluate clinical, echocardiographic and laboratory data of patients with diastolic left ventricular myocardial dysfunction infected with HIV and to present new prognostic relationships. Within the framework of a one-stage, screening, clinical study in the conditions of a multidisciplinary clinic, 240 patients with HIV infection were examined, and 136 of them showed signs of diastolic dysfunction. The development of diastolic dysfunction in HIV-infected patients is a factor provoking the development and progression of CVD, ventricular rhythm disturbances, ischemic heart disease, and anemia. Diastolic dysfunction in HIV-infected patients increases the risks of death within 2 years by 1.46 times. Increase of NT-proBNP concentration in plasma of HIV-infected patients ≥ 185.7 pg/mL is associated with the development of diastolic dysfunction in them.
- 14 February 2025
- Published by Alfmed LLC in International journal of Innovative Medicine
- No. 1,p. 10-16
Open AccessDiastolic dysfunction of the left ventricle in HIV-infected patients, clinical and prognostic relationships
Diastolic dysfunction in HIV-infected patients is a common problem, the pathway of which is based on chronic low-intensity inflammation, and whose consequences are associated with progression of chronic heart failure (CHF) and death. The aim of the study was to evaluate clinical, echocardiographic and laboratory data of patients with diastolic left ventricular myocardial dysfunction infected with HIV and to present new prognostic relationships. Within the framework of a one-stage, screening, clinical study in the conditions of a multidisciplinary clinic, 240 patients with HIV infection were examined, and 136 of them showed signs of diastolic dysfunction. The development of diastolic dysfunction in HIV-infected patients is a factor provoking the development and progression of CVD, ventricular rhythm disturbances, ischemic heart disease, and anemia. Diastolic dysfunction in HIV-infected patients increases the risks of death within 2 years by 1.46 times. Increase of NT-proBNP concentration in plasma of HIV-infected patients ≥ 185.7 pg/mL is associated with the development of diastolic dysfunction in them.
- 23 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 35,p. 25-29
Clinical and prognostic significance of determining the Tei-index in patients with HIV infection
Clarification of the presence of diastolic dysfunction, as a possible onset of chronic heart failure (CHF) with preserved LV ejection fraction, is strategic in determining the management tactics and prognosis of patients with HIV infection. It is known that chronic heart failure in HIV-infected people develops in 16–54 % of cases, accompanying the development of multiple pathologies of the myocardium and endothelium [1]. Currently, modern ultrasound equipment, if equipped with a speckle tracking option, provides ample opportunities for diagnosing CHF with preserved ejection fraction, however, this technology is not yet available in all medical institutions, so it is necessary to search for other opportunities for accurate diagnosis of CHF with preserved ejection fraction ejectionThe purpose of this work was to substantiate the use of the Tei index as an optimal and accessible indicator for diagnosing diastolic dysfunction and CHF in people with HIV infection. In a large hospital, a group of 240 patients infected with the human immunodeficiency virus (HIV) was studied over a period of four years. The study was of a one-stage, screening, clinical nature. The Tei index is also found in the literature under the name “myocardial performance index” [2]. The clinical significance of determining the Tei index in determining diastolic dysfunction in patients with HIV infection is higher than the ratio E/e’≥13, which makes this indicator recommended for echocardiography in this cohort of patients as an early marker of diastolic dysfunction and CHF.In HIV-infected patients, an increase in the Tei index of more than 0.41 is associated with the development of left ventricular diastolic dysfunction, hypertrophy, increased volume of the left atrium, pulmonary arterial hypertension, anemia and chronic kidney disease. In patients with HIV infection, with an increase in the Tei Index ≥0.41, the likelihood of developing CHF increases 10.6 times, severe CHF with NT-proBNP≥1500 pg/ml increases 8 times, anemia increases 5.75 times, 3.73 times – coronary artery disease, 3.09 times – chronic kidney disease; 2.86 times for ventricular arrhythmias and 2.29 times for pulmonary arterial hypertension.
- 23 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 35,p. 25-29
Clinical and prognostic significance of determining the Tei-index in patients with HIV infection
Clarification of the presence of diastolic dysfunction, as a possible onset of chronic heart failure (CHF) with preserved LV ejection fraction, is strategic in determining the management tactics and prognosis of patients with HIV infection. It is known that chronic heart failure in HIV-infected people develops in 16–54 % of cases, accompanying the development of multiple pathologies of the myocardium and endothelium [1]. Currently, modern ultrasound equipment, if equipped with a speckle tracking option, provides ample opportunities for diagnosing CHF with preserved ejection fraction, however, this technology is not yet available in all medical institutions, so it is necessary to search for other opportunities for accurate diagnosis of CHF with preserved ejection fraction ejectionThe purpose of this work was to substantiate the use of the Tei index as an optimal and accessible indicator for diagnosing diastolic dysfunction and CHF in people with HIV infection. In a large hospital, a group of 240 patients infected with the human immunodeficiency virus (HIV) was studied over a period of four years. The study was of a one-stage, screening, clinical nature. The Tei index is also found in the literature under the name “myocardial performance index” [2]. The clinical significance of determining the Tei index in determining diastolic dysfunction in patients with HIV infection is higher than the ratio E/e’≥13, which makes this indicator recommended for echocardiography in this cohort of patients as an early marker of diastolic dysfunction and CHF.In HIV-infected patients, an increase in the Tei index of more than 0.41 is associated with the development of left ventricular diastolic dysfunction, hypertrophy, increased volume of the left atrium, pulmonary arterial hypertension, anemia and chronic kidney disease. In patients with HIV infection, with an increase in the Tei Index ≥0.41, the likelihood of developing CHF increases 10.6 times, severe CHF with NT-proBNP≥1500 pg/ml increases 8 times, anemia increases 5.75 times, 3.73 times – coronary artery disease, 3.09 times – chronic kidney disease; 2.86 times for ventricular arrhythmias and 2.29 times for pulmonary arterial hypertension.
- 18 January 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 28 (4) , 73-81
Features of comorbidity of chronic heart failure and chronic kidney disease in patients infected with the human immunodeficiency virus
THE AIM OF THE STUDY: to identify risk factors associated with the course of chronic kidney disease (CKD), as the main manifestation of damage to the target organ – the kidney, in patients with chronic heart failure (CHF) infected with the human immunodeficiency virus (HIV).PATIENTS AND METHODS. In a multidisciplinary hospital for 28 months in 2019-2022, a one-stage screening clinical study was conducted, which included 240 patients with HIV infection. Of these, 160 people were diagnosed with CHF. Depending on the presence of CKD with a glomerular filtration rate (GFR) RESULTS. The prevalence of CKD among patients with CHF and HIV infection is 58.82 %, which is 4 times more common than in patients with HIV infection without CHF. Risk factors for the development of CKD in patients with CHF and HIV infection are smoking, alcohol and drug use, a history of chronic and acute forms of coronary artery disease, atrial fibrillation, ventricular arrhythmias, diabetes mellitus, chronic viral hepatitis C, anemia, and thrombocytopenia. Patients with CHF and CKD have a more rigid arterial wall – there is a significant excess of the stiffness indices of the aorta and peripheral arteries. Long-term use of antiplatelet agents and antiretroviral therapy aggravates the course of CHF in HIV-infected people with CKD manifestations. The concentration of NT-proBNP in the blood plasma of patients with CHF equal to or greater than 683.65 pg/ml can be considered as a diagnostic criterion for the development of CKD in HIV-infected people with a sensitivity of the method of 75.0 % and a specificity of 75.4 %, respectively. It has been proven that GFR depends on three main factors that reflect damage to the heart muscle – the concentration of NT-proBNP in blood plasma, the values of LVEF % and LVMI, which together, being included in the regression model, determine 42.2 % of the dispersion of GFR values and are decisive in the development of CKD in patients with CHF on the background of HIV infection.
- 18 January 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 28 (4) , 73-81
Features of comorbidity of chronic heart failure and chronic kidney disease in patients infected with the human immunodeficiency virus
THE AIM OF THE STUDY: to identify risk factors associated with the course of chronic kidney disease (CKD), as the main manifestation of damage to the target organ – the kidney, in patients with chronic heart failure (CHF) infected with the human immunodeficiency virus (HIV).PATIENTS AND METHODS. In a multidisciplinary hospital for 28 months in 2019-2022, a one-stage screening clinical study was conducted, which included 240 patients with HIV infection. Of these, 160 people were diagnosed with CHF. Depending on the presence of CKD with a glomerular filtration rate (GFR) RESULTS. The prevalence of CKD among patients with CHF and HIV infection is 58.82 %, which is 4 times more common than in patients with HIV infection without CHF. Risk factors for the development of CKD in patients with CHF and HIV infection are smoking, alcohol and drug use, a history of chronic and acute forms of coronary artery disease, atrial fibrillation, ventricular arrhythmias, diabetes mellitus, chronic viral hepatitis C, anemia, and thrombocytopenia. Patients with CHF and CKD have a more rigid arterial wall – there is a significant excess of the stiffness indices of the aorta and peripheral arteries. Long-term use of antiplatelet agents and antiretroviral therapy aggravates the course of CHF in HIV-infected people with CKD manifestations. The concentration of NT-proBNP in the blood plasma of patients with CHF equal to or greater than 683.65 pg/ml can be considered as a diagnostic criterion for the development of CKD in HIV-infected people with a sensitivity of the method of 75.0 % and a specificity of 75.4 %, respectively. It has been proven that GFR depends on three main factors that reflect damage to the heart muscle – the concentration of NT-proBNP in blood plasma, the values of LVEF % and LVMI, which together, being included in the regression model, determine 42.2 % of the dispersion of GFR values and are decisive in the development of CKD in patients with CHF on the background of HIV infection.
- Open Access
- 9 April 2024
- Published by Astrakhan State Medical University in Astrakhan Medical Journal
- Vol. 19 (1) , 45-57
Role of caspase-6 in the formation of severe chronic heart failure in patients infected with the human immunodeficiency virus
Caspases are a group of cysteine proteases that play a leading role in the processes of apoptosis. There is evidence that apoptosis of cardiomyocytes is the morphological basis for the formation of chronic heart failure (CHF). The aim of the study was to study the role of caspase-6 in the blood serum of patients with severe CHF infected with the human immunodeficiency virus (HIV). In 2019–2022, on the basis of a large hospital, a one-stage screening clinical study was performed with the inclusion of 240 patients infected with HIV, 160 of them (66.6 %) were diagnosed with CHF. Inclusion criteria for the study were the presence of confirmed CHF, the presence of HIV infection, stabilization of the condition due to the disease that required hospitalization, and the patient's consent to participate in the study. The criteria for exclusion from the study were social deprivation and refusal to sign informed voluntary consent, acute decompensation of CHF, acute heart failure, and oncology. The criterion for severe CHF was an increase in the level of NT-proBNP in blood plasma ≥ 1500 pg/ml. According to the results of the study, a direct close relationship was revealed between the formation of severe CHF and the content of caspase-6 in the blood serum, which may indicate an intensification of the processes of cardiomyocyte apoptosis. When the content of caspase-6 is equal to 148.35 pg/ml and above, there is a high risk of developing severe CHF with NT-pro BNP ≥ 1500 pg/ml, the chances of developing the following complications increase – CHF with low left ventricular ejection fraction (LVEF) < 40 % – 11.77 times, left ventricular hypertrophy (LVH) – 1.31 times, cachexia with a body mass index (BMI) < 18 – 18.91 times, valvular heart disease – 2.32 times, arterial hypotension - 5.96 times. In patients with CHF and HIV infection, the patterns obtained allow us to state the role of the effector enzyme apoptosis-caspase-6 as a prognostic factor for the development of such complications as LVEF < 40 %, cachexia, arterial hypotension, valvular heart disease and LVH.
- 9 April 2024
- Published by Astrakhan State Medical University in Astrakhan Medical Journal
- Vol. 19 (1) , 45-57
Open AccessRole of caspase-6 in the formation of severe chronic heart failure in patients infected with the human immunodeficiency virus
Caspases are a group of cysteine proteases that play a leading role in the processes of apoptosis. There is evidence that apoptosis of cardiomyocytes is the morphological basis for the formation of chronic heart failure (CHF). The aim of the study was to study the role of caspase-6 in the blood serum of patients with severe CHF infected with the human immunodeficiency virus (HIV). In 2019–2022, on the basis of a large hospital, a one-stage screening clinical study was performed with the inclusion of 240 patients infected with HIV, 160 of them (66.6 %) were diagnosed with CHF. Inclusion criteria for the study were the presence of confirmed CHF, the presence of HIV infection, stabilization of the condition due to the disease that required hospitalization, and the patient's consent to participate in the study. The criteria for exclusion from the study were social deprivation and refusal to sign informed voluntary consent, acute decompensation of CHF, acute heart failure, and oncology. The criterion for severe CHF was an increase in the level of NT-proBNP in blood plasma ≥ 1500 pg/ml. According to the results of the study, a direct close relationship was revealed between the formation of severe CHF and the content of caspase-6 in the blood serum, which may indicate an intensification of the processes of cardiomyocyte apoptosis. When the content of caspase-6 is equal to 148.35 pg/ml and above, there is a high risk of developing severe CHF with NT-pro BNP ≥ 1500 pg/ml, the chances of developing the following complications increase – CHF with low left ventricular ejection fraction (LVEF) < 40 % – 11.77 times, left ventricular hypertrophy (LVH) – 1.31 times, cachexia with a body mass index (BMI) < 18 – 18.91 times, valvular heart disease – 2.32 times, arterial hypotension - 5.96 times. In patients with CHF and HIV infection, the patterns obtained allow us to state the role of the effector enzyme apoptosis-caspase-6 as a prognostic factor for the development of such complications as LVEF < 40 %, cachexia, arterial hypotension, valvular heart disease and LVH.
- Open Access
- 5 April 2024
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 39 (1) , 126-134
Features of chronic heart failure on the background of thrombocytopenia in persons infected with the human immunodeficiency virus
The general context of the study is to review the characteristics of the course of chronic heart failure (CHF) in persons infected with the human immunodeficiency virus (HIV) as a part of a single-stage screening clinical trial.Aim: To determine the features of the CHF course in HIV-infected patients, depending on the presence of thrombocytopenia (TP).Material and Methods. In a multidisciplinary hospital, 240 patients with HIV infection were examined for four years, where a cohort of patients with CHF (160 people) was identified, further divided into groups of patients with TP (107 people) and without TP (53 people). Patients underwent the same amount of research, including echocardiography, non-invasive arteriography, and a detailed laboratory examination.Results. TP in patients with CHF and HIV infection is more common in smokers and people with alcohol dependence and is associated with hemodynamic disorders in the form of higher systolic and diastolic blood pressure, left atrium increase. With TP, the values of NT-proBNP in blood plasma are higher, and in the blood serum – tissue inhibitor of metalloproteinases-1, urea, bilirubin, while the concentration of sodium and potassium ions in the blood serum is lower. Anemia and leukopenia were more common in the group of patients with thrombocytopenia. Patients with TP are more adherent to taking protease inhibitors and non-steroidal anti-inflammatory drugs.Conclusion. The frequency of CHF detection in patients with HIV infection against the background of TP is almost 2 times higher and is more often accompanied by dilatation of the left atrium, higher blood pressure, an increase in TIMP-1 and a decrease in the concentration of potassium ions in the blood serum. The concentration of NT-proBNP in blood plasma has a close inverse correlation with the number of platelets in patients with CHF and TP, and the presence of severe TP ≤ 30 × 109 cells/l increases the chances of developing CHF with low left ventricular ejection fraction by 10.8 times. Smoking, possible alcohol dependence and adherence to taking protease inhibitors and NSAIDs are significant factors associated with the development of thrombocytopenia in HIV-infected patients with CHF.
- 5 April 2024
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 39 (1) , 126-134
Open AccessFeatures of chronic heart failure on the background of thrombocytopenia in persons infected with the human immunodeficiency virus
The general context of the study is to review the characteristics of the course of chronic heart failure (CHF) in persons infected with the human immunodeficiency virus (HIV) as a part of a single-stage screening clinical trial.Aim: To determine the features of the CHF course in HIV-infected patients, depending on the presence of thrombocytopenia (TP).Material and Methods. In a multidisciplinary hospital, 240 patients with HIV infection were examined for four years, where a cohort of patients with CHF (160 people) was identified, further divided into groups of patients with TP (107 people) and without TP (53 people). Patients underwent the same amount of research, including echocardiography, non-invasive arteriography, and a detailed laboratory examination.Results. TP in patients with CHF and HIV infection is more common in smokers and people with alcohol dependence and is associated with hemodynamic disorders in the form of higher systolic and diastolic blood pressure, left atrium increase. With TP, the values of NT-proBNP in blood plasma are higher, and in the blood serum – tissue inhibitor of metalloproteinases-1, urea, bilirubin, while the concentration of sodium and potassium ions in the blood serum is lower. Anemia and leukopenia were more common in the group of patients with thrombocytopenia. Patients with TP are more adherent to taking protease inhibitors and non-steroidal anti-inflammatory drugs.Conclusion. The frequency of CHF detection in patients with HIV infection against the background of TP is almost 2 times higher and is more often accompanied by dilatation of the left atrium, higher blood pressure, an increase in TIMP-1 and a decrease in the concentration of potassium ions in the blood serum. The concentration of NT-proBNP in blood plasma has a close inverse correlation with the number of platelets in patients with CHF and TP, and the presence of severe TP ≤ 30 × 109 cells/l increases the chances of developing CHF with low left ventricular ejection fraction by 10.8 times. Smoking, possible alcohol dependence and adherence to taking protease inhibitors and NSAIDs are significant factors associated with the development of thrombocytopenia in HIV-infected patients with CHF.
- Open Access
- 25 December 2023
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 12 (4) , 43-52
ARTERIAL HYPOTENSION IN HEART FAILURE PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS
HighlightsArterial hypotension is a factor aggravating the course of heart failure in HIV-infected people in 18.3% of cases, more often accompanied by the development of left ventricular hypertrophy. The risk factor for the development of arterial hypotension in persons infected with the human immunodeficiency virus (HIV) and having HF is the concentration of caspase-6 in the blood serum, which probably indicates the intensification of apoptosis processes in cardiomyocytes. The value of the glomerular filtration rate, calculated by the CKD-EPI formula with the inclusion of the level of cystatin C in the blood serum, is associated with the development of arterial hypotension. AbstractAim. To study the features of arterial hypotension in HIV-infected patients with HF in comparison with patients with normal blood pressure.Methods. The study included 44 patients with arterial hypotension (AHT) and 76 patients with normal blood pressure (BP) with heart failure (HF) and HIV admitted to a multidisciplinary hospital. All patients underwent the same number of examinations conducted personally by the author: echocardiography, noninvasive arteriography, assessment of the severity of HF using the Clinical Status Assessment Scale by V. Yu. Mareeva, six-minute walk test. Additionally, studies such as the determination of the N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP), cystatin C, caspase-6 and lipocaine 2 (NGAl) were conducted in a laboratory.Results. HIV-infected patients with HF are prone to developing AHT in 18.3% of cases. The results of the study indicate the predominance of males with low body mass index and high alcohol consumption in the group of patients with AHT. Moreover, patients with AHT are more likely to have pericardial effusion in front of the anterior wall of the right ventricle greater than 5 mm, anemia, unsuppressed viral load, left ventricular diastolic dysfunction and hypertrophy. At the same time, the level of cystatin C in their blood serum is lower, and the glomerular filtration rate is higher than in patients without AHT. The level of caspase-6 in the blood serum was significantly higher in the group of patients with AHT.Conclusion. HIV-infected patients with HF are prone to developing AHT in 18.3% of cases. The results of the study indicate a significant predominance of patients with LVH in the group of patients with AHT. The concentration of caspase-6 in blood serum equal to 148.35 pg/mL and higher turned out to be a risk factor for the development of AHT in HIV-infected patients with HF, probably indicating an intensification of apoptosis processes in cardiomyocytes. A glomerular filtration rate (GFR) equal to 47.5 mL/min/1.73 m2 and higher, calculated using the CKD-EPI formula with the inclusion of the level of cystatin C in the blood serum, is associated with a high probability of developing AHT. The pattern obtained may indicate both the activation of apoptosis processes against the background of AHT in the cells of the heart muscle, and the preservation of GFR against this background in patients with HF and HIV infection.
- 25 December 2023
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 12 (4) , 43-52
Open AccessARTERIAL HYPOTENSION IN HEART FAILURE PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS
HighlightsArterial hypotension is a factor aggravating the course of heart failure in HIV-infected people in 18.3% of cases, more often accompanied by the development of left ventricular hypertrophy. The risk factor for the development of arterial hypotension in persons infected with the human immunodeficiency virus (HIV) and having HF is the concentration of caspase-6 in the blood serum, which probably indicates the intensification of apoptosis processes in cardiomyocytes. The value of the glomerular filtration rate, calculated by the CKD-EPI formula with the inclusion of the level of cystatin C in the blood serum, is associated with the development of arterial hypotension. AbstractAim. To study the features of arterial hypotension in HIV-infected patients with HF in comparison with patients with normal blood pressure.Methods. The study included 44 patients with arterial hypotension (AHT) and 76 patients with normal blood pressure (BP) with heart failure (HF) and HIV admitted to a multidisciplinary hospital. All patients underwent the same number of examinations conducted personally by the author: echocardiography, noninvasive arteriography, assessment of the severity of HF using the Clinical Status Assessment Scale by V. Yu. Mareeva, six-minute walk test. Additionally, studies such as the determination of the N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP), cystatin C, caspase-6 and lipocaine 2 (NGAl) were conducted in a laboratory.Results. HIV-infected patients with HF are prone to developing AHT in 18.3% of cases. The results of the study indicate the predominance of males with low body mass index and high alcohol consumption in the group of patients with AHT. Moreover, patients with AHT are more likely to have pericardial effusion in front of the anterior wall of the right ventricle greater than 5 mm, anemia, unsuppressed viral load, left ventricular diastolic dysfunction and hypertrophy. At the same time, the level of cystatin C in their blood serum is lower, and the glomerular filtration rate is higher than in patients without AHT. The level of caspase-6 in the blood serum was significantly higher in the group of patients with AHT.Conclusion. HIV-infected patients with HF are prone to developing AHT in 18.3% of cases. The results of the study indicate a significant predominance of patients with LVH in the group of patients with AHT. The concentration of caspase-6 in blood serum equal to 148.35 pg/mL and higher turned out to be a risk factor for the development of AHT in HIV-infected patients with HF, probably indicating an intensification of apoptosis processes in cardiomyocytes. A glomerular filtration rate (GFR) equal to 47.5 mL/min/1.73 m2 and higher, calculated using the CKD-EPI formula with the inclusion of the level of cystatin C in the blood serum, is associated with a high probability of developing AHT. The pattern obtained may indicate both the activation of apoptosis processes against the background of AHT in the cells of the heart muscle, and the preservation of GFR against this background in patients with HF and HIV infection.